Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
GermanyIPO:
12 September 2014Website:
http://www.affimed.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Tue, 02 Jul 2024 21:42:14 GMTDividend
Analysts recommendations
Institutional Ownership
AFMD Latest News
MANNHEIM, Germany, June 05, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release first quarter 2024 results and corporate update on Wednesday, June 12, 2024. The Company will host a conference call at 8:30 a.m. EDT / 14:30 CET.
Affimed (AFMD) rallies 69% on positive follow-up efficacy data from its early to mid-stage study of the AFM24/Tecentriq combo therapy to treat heavily-pretreated EGFR wild-type NSCLC patients.
One of the oldest maxims in investing is that higher risk produces greater returns. That maxim holds particularly true across penny biotech stocks.
MANNHEIM, Germany, May 23, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that an update from the Company's AFM24-102 study in advanced EGFR wild-type (EGFRwt) non-small cell lung cancer (NSCLC) will be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) to be held in Chicago on May 31 – June 4, 2024. Patients in the study are treated with the combination of AFM24, Affimed's innate cell engager (ICE®), and atezolizumab, Roche's checkpoint inhibitor (CPI).
Several analysts predict an interest rate decrease is on the horizon for September. This could result in speculative capital shifting away from large-cap stocks.
A hammer chart pattern has emerged for Affimed N.V. (AFMD) after a recent decline in value, suggesting that the stock has established a level of support.
The consensus price target hints at a 263.4% upside potential for Affimed N.V. (AFMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Affimed N.V. (AFMD) Q4 2023 Earnings Call Transcript
Affimed N.V. (AFMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.
Affimed (NASDAQ: AFMD ) stock is on the move Friday as investors prepare for the clinical-stage biopharmaceutical company's shares to undergo a reverse split later today. AFMD stock will go through a one-for-10 reverse stock split after markets close today.
- 1(current)
What type of business is Affimed NV?
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. Affimed N.V. has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; and Roivant Sciences Ltd., as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.
What sector is Affimed NV in?
Affimed NV is in the Healthcare sector
What industry is Affimed NV in?
Affimed NV is in the Biotechnology industry
What country is Affimed NV from?
Affimed NV is headquartered in Germany
When did Affimed NV go public?
Affimed NV initial public offering (IPO) was on 12 September 2014
What is Affimed NV website?
https://www.affimed.com
Is Affimed NV in the S&P 500?
No, Affimed NV is not included in the S&P 500 index
Is Affimed NV in the NASDAQ 100?
No, Affimed NV is not included in the NASDAQ 100 index
Is Affimed NV in the Dow Jones?
No, Affimed NV is not included in the Dow Jones index
When does Affimed NV report earnings?
The next expected earnings date for Affimed NV is 09 August 2024